Edward B. Garon, MD
Immunotherapy has had a milestone impact in the field of non–small cell lung cancer (NSCLC). However, as more research unravels, investigators are unsure which set of combinations will likely have the most positive effect on their patients with advanced disease.
State of the Science Summit on Advanced Non–Small Cell Lung Cancer.
OncLive: What is the current role of immunotherapy in NSCLC?
Obviously, this is an area that has evolved very rapidly and we finally have sort of hit a point where things are stable. However, now it looks like things may change again on some level. Of course, we are awaiting future data. For the last couple of years, we have had approved agents directed against PD-1 and a PD-L1 inhibitor, atezolizumab (Tecentriq).
... to read the full story